Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Reexamination Certificate
2011-04-05
2011-04-05
Chernyshev, Olga N (Department: 1649)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
C436S149000, C435S007210
Reexamination Certificate
active
07919329
ABSTRACT:
Screening methods of use in identifying agents that affect caloric intake, food intake, appetite, and energy expenditure are disclosed herein. These methods are used to identify agents of use in treating obesity, or that can be used to decrease the weight of a subject. These methods can also be used to identify agents of use in treating anorexia or cachexia and can be used to increase appetite and to increase the weight and lean body mass of a subject.
REFERENCES:
patent: 4175122 (1979-11-01), Lazarus
patent: 4223017 (1980-09-01), Lazarus
patent: 4355025 (1982-10-01), Lazarus
patent: 4701441 (1987-10-01), Kalra
patent: 5696093 (1997-12-01), Tseng et al.
patent: 5912227 (1999-06-01), Croom, Jr. et al.
patent: 5919901 (1999-07-01), Hu et al.
patent: 5965392 (1999-10-01), Hu et al.
patent: 5989920 (1999-11-01), Gerald et al.
patent: 6001970 (1999-12-01), Cascieri et al.
patent: 6316203 (2001-11-01), Gerald et al.
patent: 7375111 (2008-05-01), Weber et al.
patent: 7462626 (2008-12-01), Weber et al.
patent: 2002/0141985 (2002-10-01), Pittner et al.
patent: WO 97/46579 (1997-12-01), None
patent: WO 01/68699 (2001-09-01), None
patent: WO 02/47712 (2002-06-01), None
patent: WO 03/026591 (2003-04-01), None
Young et al. J. Neurosci., 1998, 18 (17), pp. 6631-6640.
U.S. Appl. No. 60/256,216, filed Dec. 14, 2000, Pittner et al.
Adrian et al.,Gastroenterology89, 1070-1077 (1985).
Allen et al.,Digestion30:255-262, 1984.
Bagnol et al.,J Neurosci(Online) 19, RC26 (1999).
Barrachina et al.,Am. J. Physiol.272, R1007-11 (1997).
Barsh et al.,Nature404, 644-651 (2000).
Batterham et al.,Nature418:650-654, 2002.
Broberger, et al., “Subtypes Y1 and Y2 of the Neuropeptide Y Receptor Are Respectively Expressed in Pro-Opiomelanocortin- and Neuropeptide-Y-Containing Neurons of the Rat Hypothalamic Arcuate Nucleus,”Neuroendocrinology, 66:393-408 (1997).
Broberger-C et al.,Neuroendocrinology, 66(393-408) 1997.
Butler et al.,Endocrinology141, 3518-21 (2000).
Butler et al.,Nature Neuroscience4, 605-611 (2001).
Butler, et al., “A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse,”Endocrinology141(9):3518-3521, 2000.
Campfield et al.,Science269, 546-9 (1995).
Comuzzie et al.,Nature Genetics15:273-276, 1997.
Cone,Trends Endocrinol Metab10, 211-216 (1999).
Cowley et al.,Neuron24, 155-63. (1999).
Cowley, et al., “Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus,”Nature411:480-484, 2001.
Csiffary et al.,Brain Res506, 215-22 (1990).
Edwards et al.,Am. J Physiol. Endocrinol. Metab.281, E155-E166, (2001).
Ekblad and Sundler,Peptides23:251-261, 2002.
Elias et al.,Neuron23, 775-86 (1999).
Fan, et al., “Role of melanocortinergic neurons in feeding and the agouti obesity syndrome,”Nature385:165-168, 1997.
Farooqi et al.,N Engl J Med341, 879-84 (1999).
Glaum et al.,Mol Pharmacol50, 230-5 (1996).
Grandt et al.,Regul. Pept.51, 151-159 (1994).
Grieco et al.,J Med Chem43, 4998-5002 (2000).
Grove et al.,Neuroscience100, 731-40 (2000).
Hagan, “Peptide YY: a key mediator of orexigenic behavior,”Peptides23:377-382, 2002.
Hager et al.,Nature Genetics20:304-308, 1998.
Hakansson et al.,J Neurosci18, 559-72 (1998).
Halaas et al.,Proc Natl Acad Sci USA94, 8878-83 (1997).
Hammer et al.,Mol. Endocrin.4(11):1689-1697, 1990.
Harding and McDonald, “Identification and characterization of the emetic effects of peptide YY,”Peptides10:21-24, 1989.
Haynes et al.J Clin Invest100, 270-8 (1997).
Haynes et al.,Hypertension33, 542-7 (1999).
Heisler, et al., “Activation of central melanocortin pathways by fenfluramine,”Science0:1-3, 2002.
Hoffman et al.,Front. Neuroendocrinol.14, 173-213 (1993).
Horvath et al.,Brain Res756, 283-6 (1997).
Horvath et al.,Neuroscience51, 391-9 (1992).
Ibrahim-N et al.,Society of Neuroscience, Abstracts, 27(2)p. 1946, 2001.
Iyengar, et al., “Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?”The Journal of Pharmacology and Experimental Therapeutics289(2):1031-1040, 1999.
Kalra et al.,Endocr. Rev.20, 68-100 (1999).
Keire et al.,Am. J Physiol. Gastrointest. Liver Physiol.279, G126-131 (2000).
Kelly et al.,Neuroendocrinology52, 268-75 (1990).
Kim et al.,Diabetes49, 177-82 (2000).
Kim et al.,J Clin. Invest.105, 1005-11 (2000).
King et al.,J Neurochem73, 641-6 (1999).
Kirby et al.,J. Med. Chem.36:385-393, 1993.
Krude and Grüters,TEM11(1):15-22, 2000.
Krude et al.,Nature Genetics19:155-157, 1998.
Lee et al.,J Physiol(Lond) 515, 439-52 (1999).
Liu et al.,Biochem. J.312:827-832, 1995.
Liu et al.,Mol.&Cell.Biol.12(9):3978-3990, 1992.
Low et al., Chapter 15: “Transgenic Analysis of the Proopiomelanocortin Neuroendocrine System,” inContemporary Endocrinology: Transgenics in Endocrinology, Matzuk et al., eds., Humana Press, Totowa, NJ, 319-337, 2001.
Low et al.,J. Biol. Chem.268(33):24967-24975, 1993.
Low, M., Chapter 12: “The Identification of Neuropeptide Gene Regulatory Elements in Transgenic Mice,” inMethods in Molecular Biology, vol. 13:Protocols in Molecular Neurobiology, Longstaff & Revest, eds., Humana Press, Totowa, NJ, 181-202, 1992.
Lyznicki et al.,Amer. Family Phys.63(11):2185-2196, 2001.
Malaisse-Lagae et al.,Experientia33(7):915-917, 1977.
Marks, et al., “Role of the central melanocortin system in cachexia,”Cancer Research61:1432-1438, 2001.
Moran,Nutrition16, 858-865 (2000).
Naveilhan et al.,Peptides23(6):1087-1091, 2002.
Naveilhan, et al., “Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor,”Nature Medicine5(10):1188-1193, 1999.
Naveilhan et al.,J. Neurochem.78:1201-1207, 2001.
Okada et al., “Peripherally not centrally administered peptide YY (PYY) decreases high fat diet intake,” Abstract 520, 75thAnnual Meeting, The Endocrine Society, Las Vegas, Nevada, Jun. 9-12, 1993.
Pedersen-Bjergaard et al.,Scand. J Clin. Lab. Invest.56, 497-503 (1996).
Potter et al.,Eur. J. Pharmacol.267, 253-262 (1994).
Powis et al.,Am J Physiol274, R1468-72 (1998).
Raben et al.,Br. J Nutr.73, 517-30 (1995).
Rubinstein et al.,Neuroendocrinol.58:373-380, 1993.
Schwartz et al.,Nature404, 661-671 (2000).
Shiraishi et al.,Nutrition15, 576-9 (1999).
Slugg et al.,Neuroendocrinology72, 208-17 (2000).
Small et al.,Proc. Natl. Acad. Sci. USA94, 11686-91 (1997).
Smart & Low, Chapter 9: “Spontaneous and Induced Genetic Mutations of the POMC System,”Transgenic Models in Endocrinology, Maria Castro, ed., U. of Manchester, UK, pp. 175-194, 2001.
Soderberg et al.,J. Neurochem.75, 908-18 (2000).
Spanswick et al.,Nature390:521-525, 1997.
Tarling et al.,Intensive Care Med.23, 256-260 (1997).
Tsukada et al.,DNA and Cell Biol.13(7):755-762, 1994.
Wang X et al., Abstract,Life Science, 1994;55(11)847.
Wardlaw, S.,J. Clin. Endocrin.&Metab.86(4):1442-1446, 2001.
Yoshinaga et al.,Am J Physiol Gastrointest Liver Physiol263: G695-G701, 1992.
Young-Ji et al.,Journal of Neuroscience, 18(17)6631-6640, Sep. 1, 1998.
Zhang et al., [published erratum appears in Nature Mar. 30 1995;374(6521):479],Nature372, 425-32 (1994).
Seeley, “Melanocortin receptors in leptin effect,”Nature, 390:349 Nov. 27, 1997.
Yaswen et al. “Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin,”Nature Medicine, 5(9):1066-1070 Sep. 1999.
Cowley et al., “The Distribution and Mechanism of Action of Ghrelin in the CNS Demonstrates a Novel Hypothalamic Circuit Regulating Energy Homeostasis,”Neuron37:649-661, (Feb. 20, 2003).
Heisler et al., “Activation of Central Melanocortin Pathways by Fenfluramine,”Science297:609-611 (Jul. 26, 2002), with Supplemental Materials.
Nakazato et al., “A Role for Ghrelin in the Centralregulation of Feeding,”Nature409:194-198 (Jan. 11, 2001).
Butler Andrew
Cone Roger
Cowley Michael
Low Malcolm
Chernyshev Olga N
Klarquist & Sparkman, LLP
Oregon Health & Science University
LandOfFree
Method for screening for agents that affect food intake does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for screening for agents that affect food intake, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening for agents that affect food intake will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2737707